Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine · 13.08.2026 · 395 (7) · 660-670
DOI: 10.1056/nejmoa2602628 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.08.2026. Verfasst von Yi-Long Wu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzho…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-ret. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
- Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna.
- Department of Thoracic Surgery, Affiliated Hospital of Southwest Jiaotong University, College of Medicine, Southwest Jiaotong University, Third People's Hospital of Chengdu, Chengdu, China.
- National Cancer Center Hospital East, Kashiwa, Japan.
- Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid.
- National Taiwan University Hospital, NTU Cancer Center, Taipei.
ORCID-Profile: Yi-Long Wu, Benjamin Besse, Jonathan Goldman
Förderung
- Eli Lilly and Company
Zitieren
APA
Wu, Y. L., Hochmair, M., Yang, Y., Yang, X. N., Tsuboi, M., Paz-Ares, L., Yang, J. C., Wu, L., Kim, H. R., Rieke, D. T., Johnson, M., Besse, B., Sharma, N., Maeda, P., Peterson, P., Lin, B. K., Frimodt-Moller, B., Goldman, J., Drilon, A., & LIBRETTO-432 Trial Investigators (2026). Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine, 395(7), 660-670. https://doi.org/10.1056/nejmoa2602628
Vancouver
Wu YL, Hochmair M, Yang Y, Yang XN, Tsuboi M, Paz-Ares L, et al. Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2026;395(7):660-670. doi:10.1056/nejmoa2602628
BibTeX
@article{Wu2026,
author = {Wu, Yi-Long and Hochmair, Maximilian and Yang, Yi and Yang, Xue-Ning and Tsuboi, Masahiro and Paz-Ares, Luis and Yang, James Chih-Hsin and Wu, Lin and Kim, Hye Ryun and Rieke, Damian T and Johnson, Melissa and Besse, Benjamin and Sharma, Nivedita and Maeda, Patricia and Peterson, Patrick and Lin, Boris Kin and Frimodt-Moller, Bente and Goldman, Jonathan and Drilon, Alexander and LIBRETTO-432 Trial Investigators, LIBRETTO-432 Trial Investigators},
title = {Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {7},
pages = {660--670},
doi = {10.1056/nejmoa2602628}
}
EUVIMED